Assessment of baseline bone turnover marker levels and response to risedronate treatment: Data from a Japanese phase III trial

Bauer, 2006, Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial, J. Bone Miner. Res., 21, 292, 10.1359/JBMR.051018 Bergmann, 2009, Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club, Int. J. Clin. Pract., 63, 19, 10.1111/j.1742-1241.2008.01911.x Crandall, 2018, Bone turnover markers are not associated with hip fracture risk: a case-control study in the women’s health initiative, J. Bone Miner. Res., 33, 1199, 10.1002/jbmr.3471 Delmas, 2000, Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs, Osteoporos. Int., 11, S66, 10.1007/s001980070007 Eastell, 2003, Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate, J. Bone Miner. Res., 18, 1051, 10.1359/jbmr.2003.18.6.1051 Eastell, 2015, Relationship between pretreatment rate of bone loss and bone density response to once-yearly ZOL: HORIZON-PFT extension study, J. Bone Miner. Res., 30, 570, 10.1002/jbmr.2361 Eastell, 2018, Diagnosis of endocrine disease: bone turnover markers: are they clinically useful?, Eur. J. Endocrinol., 178, R19, 10.1530/EJE-17-0585 Fisher, 2018, Bone turnover status: classification model and clinical implications, Int. J. Med. Sci., 15, 323, 10.7150/ijms.22747 Genant, 1993, Vertebral fracture assessment using a semiquantitative technique, J. Bone Miner. Res., 8, 1137, 10.1002/jbmr.5650080915 Hagino, 2014, Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen, Bone, 59, 44, 10.1016/j.bone.2013.10.017 Johansson, 2014, A meta-analysis of reference markers of bone turnover for prediction of fracture, Calcif. Tissue Int., 94, 560, 10.1007/s00223-014-9842-y Klotzbuecher, 2000, Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis, J. Bone Miner. Res., 15, 721, 10.1359/jbmr.2000.15.4.721 Langdahl, 2018, Is there a place for bone turnover markers in the management of osteoporosis?, J. Bone Miner. Res., 33, 1197, 10.1002/jbmr.3478 Marques, 2016, Association of bone turnover markers with volumetric bone loss, periosteal apposition, and fracture risk in older men and women: the AGES-Reykjavik longitudinal study, Osteoporos. Int., 27, 3485, 10.1007/s00198-016-3675-7 Mawatari, 2017, Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials, Osteoporos. Int., 28, 1279, 10.1007/s00198-016-3848-4 Nishizawa, 2005, Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004), J. Bone Miner. Metab., 23, 97, 10.1007/s00774-004-0547-6 Nishizawa, 2013, Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition), J. Bone Miner. Metab., 31, 1, 10.1007/s00774-012-0392-y Okazaki, 2019, Factors associated with inadequate responses to risedronate in Japanese patients with osteoporosis, J. Bone Miner. Metab., 37, 185, 10.1007/s00774-018-0931-2 Orimo, 1998, Diagnostic criteria of primary osteoporosis, J. Bone Miner. Metab., 16, 139, 10.1007/s007740050038 Orimo, 2001, Diagnostic criteria for primary osteoporosis: year 2000 revision, J. Bone Miner. Metab., 19, 331, 10.1007/s007740170001 Parfitt, 1994, Osteonal and hemi-osteonal remodeling: the spatial and temporal framework for signal traffic in adult human bone, J. Cell. Biochem., 55, 273, 10.1002/jcb.240550303 Raisz, 2000, Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover, Osteoporos. Int., 11, 615, 10.1007/s001980070083 Reginster, 2008, Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy, Bone, 42, 832, 10.1016/j.bone.2008.01.021 Seibel, 2006, Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis, Clin. Biochem. Rev., 27, 123 Seibel, 2004, Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate, J. Bone Miner. Res., 19, 323, 10.1359/JBMR.0301231 Shieh, 2016, Urinary N-telopeptide and rate of bone loss over the menopause transition and early postmenopause, J. Bone Miner. Res., 31, 2057, 10.1002/jbmr.2889 Tsujimoto, 2011, PINP as an aid for monitoring patients treated with teriparatide, Bone, 48, 798, 10.1016/j.bone.2010.12.006 Vasikaran, 2016, The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis, Endocrine, 52, 222, 10.1007/s12020-016-0900-2 Vasikaran, 2011, Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards, Osteoporos. Int., 22, 391, 10.1007/s00198-010-1501-1 Vilaca, 2017, Bone turnover markers: use in fracture prediction, J. Clin. Densitom., 20, 346, 10.1016/j.jocd.2017.06.020 Yamamoto, 2013, Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide 20 μg/day administered subcutaneously in Japanese patients with osteoporosis, J. Bone Miner. Metab., 31, 199, 10.1007/s00774-012-0403-z